Assertio Holdings | DEPO - Sales Revenues


Assertio Holdings reported $29.2M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
Assertio Holdings USD 29.2M 1.92M Sep/2024
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Daiichi Sankyo JPY 587B 28.89B Mar/2026
Ironwood Pharmaceuticals USD 106.51M 58.8M Mar/2026
J&J USD 24.1B 500M Mar/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Merck USD 16.29B 110M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Pfizer USD 14.5B 3.08B Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026